Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
The Korean Society of Pediatric Hematology Oncology
GVHD prophylaxis recommendation tacrolimus (0.03 mg/kg/day i.v. by continuous infusion from day -2 and taper with an oral form until 1 year after BMT/PBSCT) methotrexate (15 mg/m2 i.v. on days 1 and 10 mg/m2 i.v. on days 3, 6, 11)
Age
0–25
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of severe aplastic anemia defined by any two or three peripheral blood criteria
and either marrow criterion.
Peripheral blood
1. Neutrophils \< 0.5 x 109/l
2. Platelets \< 20 x 109/l
3. Corrected reticulocytes \< 1%
Bone marrow
1. Severe hypocellularity (\< 25%)
2. Moderate hypocellularity (25-30%) with hematopoietic cells representing \< 30% of residual cells
No prior hematopoietic stem cell transplantation.
Age: no limits.
Performance status: ECOG 0-2.
Patients must be free of significant functional deficits in major organs, but the following eligibility criteria may be modified in individual cases.
2. Liver: total bilirubin \< 2 × upper limit of normal; ALT \< 3 × upper limit of normal.
3. Kidney: creatinine \<2 × normal or a creatinine clearance (GFR) \> 60 ml/min/1.73m2.
Patients must lack any active viral infections or active fungal infection.
Appropriate donor is available: Matched in 6/6 of A, B, DR loci.
Patients (or one of parents if patients age \< 19) should sign informed consent.
You may not be if
Pregnant or nursing women.
Malignant or nonmalignant illness that is uncontrolled or whose control may be jeopardized by complications of study therapy.
Psychiatric disorder that would preclude compliance.
Congenital aplastic anemia including Fanconi anemia.
Manipulated bone marrow.
Clareo Health | Flu+CPM+rATG Conditioning Regimes for Unrelated Bone Marrow Transplantation (UBMT)(or Mobilized Peripheral Blood)in Severe Aplastic Anemia (SAA)
